MTZ-N 0.89 CRWD-Q -2.9 AAPL-Q 0.49 HCI-N -0.2 GL-N -2.87 GAP-N -0.74 YETI-N 1
Daily Stock Opinions and Ratings

Latest Stock Buy or Sell? Make More Informed Decisions!

Today, David Driscoll commented about whether MRU-T, FCFS-N, HLMA-LN, GSK-N, TEVA-N, GE-N, FFH-T, GS-N, BAYRY-OTC, MAXR-T, VOD-Q, ING-N, ROL-N, ITRK-LON, LFUS-Q, BABA-N, STE-N, DII.B-T, SAP-T, AOS-N, PM-N are stocks to buy or sell.

  • Next Page
DON'T BUY

ING Groep NV(ING-N)

Dec 07, 2018
Europe is a basket case now, because interest rates are negative. ING's profit was lower this past quarter, because of a settlement with the Dutch government in September. ING is not growing as fast as he'd like.
David DriscollDavid Driscoll
No
Unlock Rating
$11.410

Stock price when the opinion was issued

investment companies funds
SELL

Vodafone Group PLC(VOD-Q)

Dec 07, 2018
Don't chase yield. Their dividend yield is high because the stock price is low. That yield is also not growing, because of European telecom competition; not to mention, 5G is coming so it'll be expensive for them to fund. Inflation over time will eat into their 6% dividend. VOD has been selling assets to cover this dividend. This is a tax-loss sell.
David DriscollDavid Driscoll
Unknown
Unlock Rating
$20.480

Stock price when the opinion was issued

Telecommunications
SELL

Maxar Technologies(MAXR-T)

Dec 07, 2018
They have fallen on hard times. They have deals on the table, but no guarantees, and the margins are thin in this business. This trades at a cheap multiple though at 5x forward earnings and 2x cash flow. They have to close deals and get wider margins. A tax-loss sell.
David DriscollDavid Driscoll
Unknown
Unlock Rating
$18.800

Stock price when the opinion was issued

computer software processing
DON'T BUY

Bayer AG(BAYRY-OTC)

Dec 07, 2018
Their last quarter wasn't great; there was some positive news in their pharma pipeline. They sold assets from BASF to reduce net debt, which is now at Euros 36.5 billion. The debt-to-cash flow is still high, so they have a low credit rating. Their chemical side isn't growing. EPS are down 18%, which pressured the stock. JNJ has a better phrama pipeline and credit rating.
David DriscollDavid Driscoll
Unknown
Unlock Rating
N/A

Stock price when the opinion was issued

chemicals
DON'T BUY

Goldman Sachs(GS-N)

Dec 07, 2018
Corruption in Asia has triggered a sell-off. He prefers TD, and owns no US banks. (TD operates in the US.) If they can't shake off these corruption charges, then GS will be in the penalty box for a while
David DriscollDavid Driscoll
No
Unlock Rating
$179.670

Stock price when the opinion was issued

investment companies funds
COMMENT

Fairfax Financial(FFH-T)

Dec 07, 2018
Been stuck in a trading range the past five years: Buy or wait? In 2008, FFH made a lot of money shorting the market, and in the past year he's taken off those shorts and sold all his bonds till he's sitting in cash. Not a good strategy. The combined ratios in their insurance business is high vs. peers. Prem Watsa has been successful buying bad insurance companies and turning them around, but has been successful only sometimes. That said, he likes the future of FFH--as they allocate their cash.
David DriscollDavid Driscoll
Owned
Unlock Rating
$614.000

Stock price when the opinion was issued

insurance
SELL

General Electric(GE-N)

Dec 07, 2018
Tax-loss sell it. Most recently, they are recalling power-generation units around the world, which will further drag down revenues. 20 years ago, this was a quality company. No longer.
David DriscollDavid Driscoll
Unknown
Unlock Rating
$7.010

Stock price when the opinion was issued

electrical electronic
BUY

Teva Pharmaceutical(TEVA-N)

Dec 07, 2018
TEVA vs. GSK Teva is in turnaround with a lot of debt to pay off. They need a boast from their future products moving forward. GSK is higher quality with higher credit rating, and lack Teva's debt woes. GSK is the better bet.
David DriscollDavid Driscoll
No
Unlock Rating
$19.410

Stock price when the opinion was issued

biotechnology pharmaceutical
DON'T BUY

GlaxoSmithKline PLC(GSK-N)

Dec 07, 2018
TEVA vs. GSK Teva is in turnaround with a lot of debt to pay off. They need a boast from their future products moving forward. GSK is higher quality with higher credit rating, and lack Teva's debt woes. GSK is the better bet.
David DriscollDavid Driscoll
No
Unlock Rating
$37.300

Stock price when the opinion was issued

biotechnology pharmaceutical
TOP PICK

Halma plc(HLMA-LN)

Dec 07, 2018
They produce safety and testing equipment found in buildings, such as elevators. In bad markets, HLMA does not go down. A steady company. They have only 25% of revenues in UK/Europe. The dividend has been rising 7-8% yearly. A safe, defensive stock. (Analysts’ price target is $1404.17)
David DriscollDavid Driscoll
Owned
Unlock Rating
N/A

Stock price when the opinion was issued

0
TOP PICK

First Cash Financial Services(FCFS-N)

Dec 07, 2018
They own pawn stores in America, Mexico and now Colombia . They do well when the economy weakens and trade a lot in gold jewllery. As the US dollar falls and price rises, he'd rather own this than gold or a gold ETF. Dividend has been rising 15% yearly. (Analysts’ price target is $94.14)
David DriscollDavid Driscoll
Owned
Unlock Rating
$81.230

Stock price when the opinion was issued

banks
TOP PICK

Metro Inc (A)(MRU-T)

Dec 07, 2018
Purely defensive. They've been increasing their dividend 10% yearly. A place to hide during the storm. (Analysts’ price target is $46.96)
David DriscollDavid Driscoll
Owned
Unlock Rating
$45.940

Stock price when the opinion was issued

food stores

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

DRS-Q -0.38$47.59
C-N 4.095$91.595
JPM-N -2.15$286.55
BLK-N -65.3$1046.16
MS-N -2.46$141.51

Today's Top Picks

MTZ-N 0.89$173.27
CRWD-Q -2.9$473.28
AAPL-Q 0.49$209.11
HCI-N -0.2$141.06
GL-N -2.87$117.82

Popular Articles

Latest Sell Signals

PFE-N -0.74$24.61
INTC-Q -0.38$22.92
F-N -0.31$11.57
IBM-N -1.09$282.7
KVUE-N -0.41$21.41

Most Recent Experts

Gordon Reid

Gordon Reid

GoodReid Investment Counsel

The Panic-Proof Portfolio (Stockchase Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Larry Berman CFA, CMT, CTA

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Greg Dean

Greg Dean

Cambridge Global Asset Management

Stockchase Insights

Stockchase Insights

5i Research

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: hello@stockchase.com.

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© Stockchase Inc. by Wealthica